Solvay Pharmaceuticals Sign Extensive Collaboration Agreement

[Guest guest]

AEterna subsidiary Zentaris and Solvay Pharmaceuticals Sign Extensive

Collaboration Agreement

QUEBEC CITY, Quebec, FRANKFURT/MAIN, Germany, and BRUSSELS, Belgium,

January 23 /PRNewswire/ -- - Development of novel compound class for a

broad variety of indications offers huge potential

All amounts are in Canadian dollars

AEterna Laboratories Inc. (TSX: AEL; Nasdaq: AELA) today announced

that its 100%-owned subsidiary Zentaris GmbH and Solvay

Pharmaceuticals B.V. have entered into an extensive collaboration

agreement. Based on the agreement, Solvay Pharmaceuticals and Zentaris

will jointly push ahead Zentaris' research project aimed at developing

novel, low molecular weight and orally-bioavailable peptidomimetic

LHRH (Luteinizing Hormone Releasing Hormone) antagonists. Potential

indications include endometriosis, uterus myoma, benign prostatic

hyperplasia (BPH), as well as malignant disorders such as breast and

prostate cancer.

read the rest here:

http://www.prnewswire.co.uk/cgi/news/release?id=115729